Methods of generating natural killer cells

Patent metadata

Field	Value
Publication number	US-9464274-B2
Application number	US-201414547084-A
Country	US
Kind code	B2
Filing date	Nov 18, 2014
Priority date	Jul 13, 2010
Publication date	Oct 11, 2016
Grant date	Oct 11, 2016

Abstract

Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer or viral infection.

First claim

What is claimed is:

1. A method of treating an individual having tumor cells, comprising administering to said individual a therapeutically effective amount of NK cells, wherein said NK cells have been produced by a method comprising:
(a) seeding a population of hematopoietic stem or progenitor cells in a first medium comprising interleukin-15 (IL-15) and, optionally, one or more of stem cell factor (SCF) and interleukin-7 (IL-7), wherein said IL-15 and optional SCF and IL-7 are not comprised within an undefined component of said medium, and wherein the first medium further comprises one or more of Fms-like-tyrosine kinase 3 ligand (Flt3-L), thrombopoietin (Tpo), interleukin-2 (IL-2), or heparin, such that the population expands, and a plurality of hematopoietic stem or progenitor cells within said population of hematopoietic stem or progenitor cells differentiate into NK cells during said expanding; and
(b) next expanding the NK cells from step (a) in a second medium comprising interleukin-2 (IL-2), to produce a population of activated NK cells.

2. The method of claim 1 , wherein said tumor cells are primary ductal carcinoma cells, glioblastoma cells, leukemia cells, acute T cell leukemia cells, chronic myeloid lymphoma (CML) cells, acute myelogenous leukemia cells, chronic myelogenous leukemia (CML) cells, lung carcinoma cells, colon adenocarcinoma cells, histiocytic lymphoma cells, multiple myeloma cells, colorectal carcinoma cells, colorectal adenocarcinoma cells, prostate cancer cells, or retinoblastoma cells.

3. The method of claim 1 , wherein said tumor cells are blood cancer cells.

4. The method of claim 2 , wherein said tumor cells are acute myelogenous leukemia (AML) cells, chronic lymphocytic leukemia (CLL) cells, or multiple myeloma cells.

5. The method of claim 1 , wherein the individual has a deficiency of natural killer cells.

6. The method of claim 1 , wherein said method of treating further comprises administering to said individual isolated placental perfusate or isolated placental perfusate cells.

7. The method of claim 1 , wherein said method of treating further comprises administering to said individual an effective amount of an immunomodulatory compound.

8. The method of claim 7 , wherein the immunomodulatory compound is lenalidomide or pomalidomide.

9. The method of claim 1 , wherein said tumor cells are solid tumor cells.

10. The method of claim 1 , wherein the individual has received a bone marrow transplant.

11. The method of claim 10 , wherein the individual has received an immunosuppressant in addition to the bone marrow transplant.

12. The method of claim 10 , wherein the individual who has a bone marrow transplant exhibits one or more symptoms of graft-versus-host disease (GVHD).

13. The method of claim 1 , wherein the individual has received at least one dose of a TNFα inhibitor.

14. The method of claim 1 , wherein the composition is prepared for administration with an anti-cancer drug.

15. The method of claim 1 , wherein the NK cells are CD3 − CD56 + CD16 − .

16. The method of claim 15 , wherein the NK cells are additionally CD94 + CD117 + .

17. The method of claim 15 , wherein the NK cells are additionally CD161 − .

18. The method of claim 15 , wherein the NK cells are additionally NKG2D + .

19. The method of claim 15 , wherein the NK cells are additionally NKp46 + .

20. The method of claim 15 , wherein the NK cells are additionally CD226 + .

Assignees

• Anthrogenesis Corp

Inventors

• Hariri Robert J
• Heidaran Mohammad A
• Jasko Stephen
• Kang Lin
• Law Eric
• Pal Ajai
• Stout Bhavani
• Voskinarian-Berse Vanessa
• Zeitlin Andrew
• Zhang Xiaokui

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P35/04

  specific for metastasis · CPC title

• A61P35/02

  specific for leukemia · CPC title

• C12N2501/2307

  Interleukin-7 (IL-7) · CPC title

• C12N2500/30

  Organic components · CPC title